Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
65 participants
INTERVENTIONAL
2021-03-09
2021-11-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
NCT00082576
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
NCT00084227
The Effect of Chloroquine in the Treatment of Patients With Dengue
NCT00849602
Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)
NCT04002687
Azithromycin Combination Therapy for the Treatment of Severe Malaria
NCT01374126
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AT-752 250 mg single dose
AT-752 administered orally, 250 mg on Day 1
AT-752
Parallel Assignment
Placebo -single dose
Matching placebo administered orally on Day 1
Placebo
Parallel Assignment
AT-752 500 mg single dose
AT-752 administered orally, 500 mg single doses on Day 1 and Day 7
AT-752
Parallel Assignment
Placebo- single dose
Matching placebo administered orally on Day 1 and Day 7
Placebo
Parallel Assignment
AT-752 1000 mg single dose
AT-752 administered orally, 1000 mg single dose on Day 1
AT-752
Parallel Assignment
Placebo - single dose
Matching placebo administered orally on Day 1
Placebo
Parallel Assignment
AT-752 1500 mg single dose
AT-752 administered orally, 1500 mg single dose on Day 1
AT-752
Parallel Assignment
Placebo: single dose
Matching placebo administered orally on Day 1
Placebo
Parallel Assignment
AT-752 - 1000 mg QD multiple doses
AT-752 - administered orally, 1000 mg once daily (QD) for 7 days
AT-752
Parallel Assignment
Placebo - Administered once daily (QD)
Matching placebo administered orally once daily (QD) for 7 days
Placebo
Parallel Assignment
AT-752 - 750 mg twice daily (BID)
AT-752 administered orally, 750 mg twice daily (BID) for 4 days plus one dose on Day 5.
AT-752
Parallel Assignment
Placebo - Administered twice daily (BID)
Matching placebo administered orally twice daily (BID) for 4 days plus one dose on Day 5.
Placebo
Parallel Assignment
AT-752 - 750 mg three times daily (TID)
AT-752 administered orally, 750 mg three times daily (TID) for 4 days plus one dose on Day 5.
AT-752
Parallel Assignment
Placebo - Administered TID
Matching placebo administered orally (TID) for 4 days plus one dose on Day 5.
Placebo
Parallel Assignment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AT-752
Parallel Assignment
Placebo
Parallel Assignment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must agree to use protocol-specified methods of contraception
3. Negative pregnancy test
4. Willing to comply with the study requirements and to provide written informed consent
Exclusion Criteria
2. Abuse of alcohol or drugs
3. Use of other investigational drugs within 30 days of dosing
4. Other clinically significant medical conditions
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atea Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atea Study Site
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhou X-J, Lickliter J, Montrond M, Ishak L, Pietropaolo K, James D, Belanger B, Horga A, Hammond J. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrob Agents Chemother. 2024 May 2;68(5):e0161523. doi: 10.1128/aac.01615-23. Epub 2024 Mar 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AT-02A-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.